HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Neutral rating on Sage Therapeutics (NASDAQ:SAGE) and maintained a $25 price target.
August 02, 2024 | 11:17 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Neutral rating on Sage Therapeutics and maintained a $25 price target.
The reiteration of a Neutral rating and maintenance of the $25 price target suggests that the analyst does not foresee significant short-term changes in the stock's performance. This is likely to result in a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100